Active ingredient comprising galactomannans derived from Medicago sativa and its cosmetic uses

Abstract

The present invention relates to a cosmetic active ingredient comprising galactomannans obtained from the seeds of Medicago sativa and its cosmetic uses. This active ingredient has a complexion-perfecting effect, is suitable for all skin types and ethnicities: Caucasian, Asian, African American, and Hispanic American, regardless of age.

Description

Title of the invention: Active ingredient comprising galacto-mannans from Medicago sativa and its cosmetic uses Technical field

[0001] The invention relates to a cosmetic active ingredient comprising galactomannans obtained from the seeds of Medicago sativa and its cosmetic uses. This active ingredient advantageously has a perfecting effect on mixed and multi-ethnic complexion, that is to say intended for all types of healthy skin, whether Caucasian, Asian, African-American, or Hispanic-American. State of the art

[0002] Over time, society has continued to evolve the standards of ideal beauty. However, despite cultural differences, the cosmetics industry has long remained biased towards Western standards to promote its products. Even though makeup shade variations emerged in the 1970s in the United States and opened the doors to a more inclusive beauty, it was only with the rise of social media and its influencers from all corners of the world that this movement began to really take off. Driven by the emergence of diversity, equality, and inclusion, a re-prioritization of individual needs has gradually created a new face of beauty where each individual feels neither excluded nor marginalized. These principles go hand in hand with the increased demand for ultra-personalized care, motivated by all age groups.

[0003] This approach now extends beyond skin color and tends to encompass the specific characteristics of each ethnicity, gender, or stage of life. The study of these structural and functional specificities of the skin has aroused strong interest in dermatology and has allowed the cosmetics industry to exalt “plural beauty.” Whether male, female, young, old, or from the four corners of the world, all skin types have their particularities and problems.

[0004] Nevertheless, men and women share common expectations in terms of moisturizing and anti-aging care, to which are added complexion-perfecting care. A radiant and even complexion is therefore a universal concern regardless of ethnicity and gender. Thus, despite differences in terms of needs and concerns according to ethnicity, age and gender, three major axes of beauty are emerging to meet the universal expectations of skincare consumers: namely skin quality, complexion, and anti-aging.

[0005] For these reasons, there is a need for a cosmetic active ingredient that can meet the concerns and expectations of mixed and multi-ethnic beauty.

[0006] To meet this need, the inventor was particularly interested in the remarkable properties of alfalfa, already known for its beneficial effects on Caucasian skin, to develop a new naturally derived ingredient meeting the expectations of mixed and multi-ethnic beauty.

[0007] Thus, the inventor has developed a new cosmetic active ingredient, namely an extract of Medicago saliva, enriched with galactomannans making it possible to confer mixed and multi-ethnic cosmetic benefits, in particular a complexion-perfecting effect intended for all healthy skin types, whether Caucasian, Asian, African-American, or Hispanic-American. Summary of the invention

[0008] The invention thus relates to the cosmetic use of a cosmetic active ingredient comprising at least one hydrolyzate comprising galactomannans obtained from the seeds of Medicago saliva, for its complexion-perfecting effect on healthy skin, preferably healthy Caucasian and Asian and Afro-American and Hispanic-American skin.

[0009] According to a preferred object, the invention relates to the cosmetic use of said cosmetic active ingredient for its complexion-perfecting and moisturizing effects, but also its anti-aging effects. These cosmetic effects combined in a single cosmetic active ingredient are of particular interest in meeting the needs of mixed and multi-ethnic beauty.

[0010] In this context, the inventor evaluated the mixed and multi-ethnic cosmetic benefits of this cosmetic active ingredient, in particular the complexion-perfecting effect for several skin types, namely Caucasian and Asian and African-American and Hispanic-American skin. The performance of the active ingredient was thus demonstrated from the cell to the volunteer. First of all, the pro-collagen activity was measured on fibroblasts from female and male volunteers, of different ages and different ethnicities. The cosmetic active ingredient according to the invention also demonstrated its complexion-perfecting power, that is to say an improvement in the radiance of the complexion as well as the homogenization of the complexion, in particular a reduction in pigmentary disorders, on all skin types, meeting consumer expectations.

[0011] According to another aspect, the invention also relates to a new cosmetic active ingredient comprising at least one extract obtained from the seeds of Medicago sativa, in which the extract of Medicago sativa comprises, by weight of the total weight of the extract, at least 35% of sugars and at most 25% of proteins.

[0012] According to a preferred object of the invention, the sugar fraction of the extract comprises at least 60% of galactomannans by weight of the total weight of the sugars of the extract, the extract comprising at least 60% of galactomannans in the form of oligo-galactomannans or poly-galactomannans, with molecular masses between 360 Da and 1260 kDa, by weight of the total weight of sugars in the extract, which has the effect of improving the cosmetic benefits for each consumer.

[0013] More preferably, the extract according to the invention comprises at least 30% of galactomannans with molecular masses between 3.6 kDa (DP20) and 1260 kDa (DP7000), by weight of the total weight of the sugars in the extract.

[0014] The cosmetic active ingredient comprising the extract of Medicago sativa can be in different forms: in liquid form or in solid form or in film form, preferably it is in liquid form. This advantageously comprises at least one excipient chosen from a preservative, an antioxidant, a stabilizer, an atomization support, and / or their combination.

[0015] According to another particularly preferred subject, the extract of Medicago sativa is a hydrolyzate of Medicago sativa, more preferably an enzymatic hydrolyzate.

[0016] The active ingredient according to the invention can be obtained by different methods. However, according to a particularly interesting embodiment, the active ingredient according to the invention is obtained by a method comprising the following steps: a. Solubilization of Medicago sativa seeds in water at a rate of at least 50g / l, b. Extraction by hydrolysis, preferably enzymatic hydrolysis, c. Separation of soluble and insoluble phases, d. Heat treatment, e. Concentration of the soluble phase, f. Purification by ion chromatography, g. Optionally, filtration and sterilizing filtration.

[0017] Thus, the invention also relates to the process for extracting and preparing the active ingredient described above.

[0018] On the other hand, the invention also aims at a cosmetic composition comprising at least 0.1% of a cosmetic active ingredient according to any of the preceding objects, by weight of the total weight of the composition.

[0019] Finally, the invention relates more advantageously to the use of this cosmetic active ingredient according to the invention or of the composition comprising it, intended for a cosmetic treatment for men and women, in topical application to the skin, preferably to healthy skin of Caucasian, Asian, African-American, but also Hispanic-American type for multiple cosmetic benefits, namely a complexion-perfecting, moisturizing and anti-aging effect, regardless of the skin type.

[0020] Also, the inventor has developed an active ingredient of natural, mixed and multi-origin ethnic meeting universal cosmetic expectations in terms of inclusive beauty.

[0021] Other characteristics and advantages will emerge from the detailed description of the invention, the examples and the figures which follow. Brief description of the Figures

[0022] [Fig-1] represents the effect of the active ingredient according to the invention formulated at 2.5% in emulsion on cell renewal in young Caucasian volunteers compared to a placebo formula.

[0023] [Fig.2] represents the effect of the active ingredient according to the invention formulated at 2.5% in emulsion on cell renewal of mature Caucasian volunteers compared to a placebo formula.

[0024] [Fig.3] represents the effect of the active ingredient according to the invention formulated at 2.5% in emulsion on the quality of the fibers of the dermal matrix of mature Caucasian volunteers after 42 days of twice-daily treatment.

[0025] [Fig.4] represents the effect of the active ingredient according to the invention formulated at 2.5% in emulsion on the radiance parameter of the complexion of young and mature panels, 15 minutes after a single application as well as after 7, 21 or 42 days of treatment. Detailed description of the invention

[0026] Definition

[0027] By "inclusive beauty", "universal beauty" or "mixed and multi-ethnic beauty" within the meaning of the present invention, is meant an improvement in the quality of the skin, the radiance of the complexion, the homogeneity of the complexion, and the hydration of the skin, regardless of whether the healthy skin is Caucasian, Asian, African-American, or Hispanic-American, whether it concerns men or women and regardless of their age.

[0028] For the purposes of the present invention, the term "Medicago sativa extract" means at least one molecule or a mixture of at least two molecules obtained from a raw material, namely alfalfa, i.e. the species Medicago sativa, regardless of the extraction process of said molecule(s). It may be, for example, an extract obtained by aqueous and / or hydroalcoholic and / or hydroglycolic extraction and / or obtained after at least one hydrolysis step, for example enzymatic or acid.

[0029] For the purposes of the invention, the term "Medicago sativa hydrolysate" means an extract from the plant species Medicago sativa, obtained by a process comprising at least one step of hydrolysis of Medicago sativa. The term "Medicago sativa hydrolysate" excludes molecules produced solely by fermentation of Medicago sativa by a microorganism or an infusion / decoction / maceration of Medicago sativa. Thus, for the purposes of the invention, such an extract is an ingredient derived from the natural product obtained by specific and defined chemical and / or biological processes aimed at modifying it chemically, modifications which are intentional, and which make it possible to obtain structures of molecules which are therefore no longer identical to the molecules present in nature.

[0030] By "active ingredient" within the meaning of the invention, we mean an extract comprising at least one molecule, preferably a set of molecules having a cosmetic effect, in particular when applied topically, in particular the cosmetic effect is a complexion-perfecting effect.

[0031] By "complexion perfector" within the meaning of the invention, we mean an improvement in the radiance of the complexion and a reduction in the signs of post-inflammation hyperpigmentation of the skin.

[0032] Active ingredient according to the invention

[0033] The subject of the present invention is therefore a cosmetic active ingredient comprising at least one extract obtained from the seeds of Medicago saliva, in which the extract of Medicago sativa comprises, by weight of the total weight of the extract, at least 35% of sugars and at most 25% of proteins.

[0034] Medicago sativa, also known as alfalfa or lucerne, is a fodder plant native to Asia whose cultivation has spread throughout the world, particularly for its nutritional qualities and medicinal properties. It is adorned with clusters of flowers in different shades of purple which then develop into fruits in the form of spiral pods, these include the seeds. In addition, the roots are home to microorganisms that establish a nitrogen-fixing symbiosis, helping both the development of the plant and the enrichment of the soil. The cultivation of alfalfa is therefore of great ecological importance for the environment and biodiversity, in addition to its nutritional and medicinal properties.

[0035] Access (as defined in the Nagoya Protocol) to the plant raw material (Medicago sativa) was carried out in accordance with the national APA (Access and Benefit Sharing) regulations of the country of origin, France.

[0036] Alfalfa seeds are naturally rich in polysaccharides of the mannose and galactose polymer type, which the inventor has remarkably exploited in order to obtain an extract enriched in galactomannans of interest.

[0037] The active ingredient according to the invention comprising the extract of Medicago sativa is preferably composed mainly of galactomannans, more preferably the extract comprises at least 60% of galactomannans, by weight of the total weight of the total sugars included in the extract. This composition was determined by ion chromatography.

[0038] The inventor characterized the sugars present in the extract according to the invention by chromatography (LC-CAD). The total sugar content, for its part, can be determined according to the DUBOIS method (Dubois M. et al., Analytical chemistry, 28, 3, 350-356, 1956).

[0039] According to a preferred object, the extract according to the invention comprises at least 60% of sugars with molecular masses between 360 Da and 1260 kDa (DP2 to DP7000), by weight of the total weight of the sugars in the extract.

[0040] According to another preferred subject of the invention, the extract according to the invention comprises at least 30% of sugars with molecular masses between 3.6 kDa (DP20) and 1260 kDa (DP7000), by weight of the total weight of the sugars in the extract.

[0041] Very preferably, the extract according to the invention comprises at least 60% of sugars with molecular masses between 360 Da and 1260 kDa (DP2 and DP7000), by weight of the total weight of the sugars in the extract, as well as at least 30% of sugars with molecular masses between 3.6 kDa (DP20) and 1260 kDa (DP7000), by weight of the total weight of the sugars in the extract.

[0042] Finally, according to another object, the extract comprises at most 25% of sugars with molecular masses less than or equal to 180 Da (DPI), by weight of the total weight of the sugars in the extract, preferably at most 20% of sugars with molecular masses less than or equal to 180 Da.

[0043] The composition of the sugars constituting the extract according to the invention has also been determined; this can in particular be determined by ion chromatography. The extract advantageously comprises galactose, mannose, glucose and fructose. Very advantageously, it mainly comprises galactose and mannose.

[0044] The extract according to the invention is also rich in galactomannans. To improve and optimize this enrichment, the extract is very preferably obtained using hydrolysis, even more preferably at least enzymatic hydrolysis. Thus, the extract of Medicago sativa according to the invention is preferably a hydrolyzate, more preferably an enzymatic hydrolyzate.

[0045] The extract according to the invention can be obtained by any extraction process. However, in a particularly preferred manner, the extract is capable of being obtained by a process comprising at least the following steps: a. Solubilization of Medicago sativa seeds in water at a rate of at least 50g / l, b. Extraction by hydrolysis, preferably enzymatic hydrolysis, c. Separation of soluble and insoluble phases, d. Heat treatment, e. Concentration of the soluble phase, f. Purification by ion chromatography, g. Optionally, filtration and sterilizing filtration.

[0046] The cosmetic active ingredient according to the invention can also advantageously comprise at least one excipient selected from a preservative, an antioxidant, a stabilizer, an atomization support, and / or their combination.

[0047] The extract according to the invention present in the cosmetic active ingredient can then be in liquid form or in solid form or in film form.

[0048] When it is presented in liquid form, the active ingredient according to the invention consists exclusively of the extract of Medicago sativa accompanied by a stabilizer and / or preservation system.

[0049] The extract in liquid form is preferably in the form of a clear liquid aqueous solution, with a weak odor and a light yellow to yellow color.

[0050] When it is in liquid form, the dry matter content of the extract can be determined by weighing the residues resulting from drying the extract according to the invention at 105°C in an oven until a constant weight is obtained. Preferably, the extract according to the invention in liquid form has a dry matter content of 20 g / L to 70 g / L, preferably 20 to 55 g / L, even more preferably 22 g / L to 32 g / L.

[0051] When it is in solid form, the active ingredient according to the invention is preferably constituted by the extract of Medicago sativa as previously described and by a carrier chosen from maltodextrin, gum arabic or soy lecithin. According to a particularly suitable embodiment, the extract represents at least 10% by weight of the active ingredient and the carrier at most 90% by weight of the active ingredient.

[0052] In the case of a solid form in which the active ingredient is associated with a carrier, the contents of proteins, sugars and galactomannans relative to the dry matter in the active ingredient can be modified since the carriers (maltodextrin, gum arabic) are exclusively saccharides.

[0053] The active ingredient according to the invention can also be presented in the form of a film as described in patent FR3079145. In this case, the Medicago sativa extract preferably represents at least 0.1% by weight of the film.

[0054] When it is in the form of a film, the active ingredient comprises: - at least the extract of Medicago sativa according to the invention. - at least one mineral filler, and - at least one polymer of natural origin, and - at least one plasticizer, and - at least one surfactant.

[0055] The polymer of natural origin can be chosen from: Pectin, Tamarind gum, Alginate, Pullulan, Psyllium, Xanthan, Guar, Tara, Carob, Agar, Gum arabic, Gellan, Dextran, Carrageenan, Cellulose, Konjac and Chitosan.

[0056] The plasticizer can be chosen from: Glycerol, Sorbitol, Sucrose, Erythritol, Urea, Propylene glycol and Butylene glycol.

[0057] The mineral filler can be chosen from: calcium carbonate, green clay, kaolin, perlite, talc, magnesium silicate, mica, diatomaceous sericite, silica, calcium sulfate, calcium chloride, potassium chloride, iron oxide and zinc oxide.

[0058] The active ingredient may further comprise a pigment for coloring the film.

[0059] Composition according to the invention

[0060] The active ingredient according to the invention is intended to be integrated into a composition, in particular a composition comprising at least 0.1% by weight of said active ingredient and a physiologically acceptable medium, preferably a cosmetically acceptable medium.

[0061] These compositions may be in particular in the form of oil-in-water emulsions, water-in-oil emulsions, multiple emulsions (Water / Oil / Water or Oil / Water / Oil) which may optionally be microemulsions or nanoemulsions, or in the form of solutions, suspensions, hydrodispersions, aqueous gels, powders, or foundation or in the form of a film. They may be more or less fluid and have the appearance of creams, emulsions, gels, masks or any other aspects known to those skilled in the art.

[0062] Preferably, these may be compositions comprising between 0.1 and 20% of the active ingredient according to the invention, in particular in liquid form, more preferably between 0.5 and 10%.

[0063] These compositions comprise, in addition to the active ingredient, a physiologically acceptable medium such as a cosmetically acceptable medium, that is to say which does not cause sensations of discomfort for the user such as redness, tightness or tingling.

[0064] The compositions according to the invention may also contain as an ingredient at least one compound chosen from: - oils, which may be chosen in particular from silicone oils, linear or cyclic, volatile or non-volatile, - waxes, such as ozokerite, polyethylene wax, beeswax or camauba wax, - silicone elastomers, - surfactants, preferably emulsifying surfactants, whether non-ionic, anionic, cationic or amphoteric, - co-surfactants, such as linear fatty alcohols, - thickeners and / or gelling agents, - humectants, such as polyols like glycerin, - colorants, preservatives, fillers, - tensors, - sequestrants, - perfumes, - and their mixtures, without this list being exhaustive.

[0065] Examples of such ingredients are cited in particular in the CTFA Dictionary (International Cosmetic Ingredient Dictionary and Handbook published by the Personal Care Product Council).

[0066] Of course, those skilled in the art will take care to choose the possible complementary compounds, active or non-active, and their quantity, in such a way that the advantageous properties of the mixture are not, or not significantly, altered by the envisaged addition.

[0067] Process for preparing the extract according to the invention

[0068] The extract constituting or contained in the active ingredient according to the invention can be obtained by any means.

[0069] However, according to a preferred embodiment, the extraction method comprises at least one extraction step from Medicago saliva, such as at least one hydrolysis, preferably at least one enzymatic hydrolysis, more preferably at least one enzymatic hydrolysis using a carbohydrase.

[0070] According to a particularly suitable embodiment, the active ingredient according to the invention is obtained by implementing the following steps: a. Solubilization of Medicago sativa seeds in water at a rate of at least 50g / l, b. Extraction by hydrolysis, preferably enzymatic hydrolysis, c. Separation of soluble and insoluble phases, d. Heat treatment, e. Concentration of the soluble phase containing galactomannans, f. Purification by ion chromatography to enrich in galactomannans, g. Optionally, filtration and sterilizing filtration.

[0071] The heat treatment step is advantageously carried out to inactivate the enzyme(s) present. This inactivation is then carried out according to the recommendations of the supplier of the enzyme(s) used.

[0072] The separation of the soluble and insoluble phases is carried out by any means known to those skilled in the art, for example by centrifugation, filtration or decantation. The separation of the soluble and insoluble phases is carried out to recover the soluble phase containing the galactomannans.

[0073] The extract obtained at this stage can optionally be further concentrated. Preferably the extract is purified, preferably by successive ultrafiltration steps through membranes of different porosity, retaining the galactomannans at each step and / or by a chromatographic type method. In the context of the invention, the extract obtained after the step of concentration of the soluble phase, undergoes at least one purification step in order to enrich the galacto-mannan content, preferably the purification is carried out by means of ion chromatography.

[0074] The extract obtained after hydrolysis and concentration is an extract of Medicago saliva, and constitutes a first form of the active ingredient according to the invention, then appearing in liquid form.

[0075] Another form of the active ingredient according to the invention is obtained after hydrolysis, concentration and purification and is also in liquid form.

[0076] The extract obtained can then be dried and combined or not with a support, to be presented in solid form. This phase can be carried out by implementing the following steps: - an atomization carrier, preferably maltodextrin, is added to the Medicago saliva extract, at most 90% (mass / volume); - this solution is then concentrated under vacuum; - antimicrobial treatment can be carried out; - atomization makes it possible to obtain a powder.

[0077] The steps of the processes described above, taken individually, are customary in the field of extractions of active ingredients from natural raw materials and those skilled in the art are able to adjust the reaction parameters on the basis of their general knowledge.

[0078] Cosmetic uses

[0079] According to one aspect, the invention relates to the cosmetic use of a cosmetic active ingredient comprising at least one hydrolyzate comprising galactomannans obtained from the seeds of Medicago sativa, for its complexion-perfecting effect on healthy multi-ethnic skin.

[0080] Preferably, the cosmetic benefits of this cosmetic active ingredient comprising at least one hydrolyzate enriched with galactomannans obtained from the seeds of Medicago sativa, are said to be mixed and multi-ethnic. Also, the invention preferably aims at the cosmetic use of this active ingredient, for healthy Caucasian and Asian and African-American and Hispanic-American skin. Indeed, the inventor observed in the context of his work, that such an active ingredient made it possible to meet the needs of mixed and multi-ethnic beauty.

[0081] More preferably, the invention aims at the cosmetic use of this active ingredient for its complexion-perfecting, moisturizing and anti-aging effects.

[0082] To achieve this, this active ingredient comprising at least one hydrolyzate enriched in galactomannans obtained from the seeds of Medicago sativa, is advantageously a hydrolyzate comprising at least 60% of galactomannans by weight of the total weight of the sugars from the hydrolyzate.

[0083] According to a variant, the active ingredient according to any of the objects previously described, or the composition comprising it is intended to be used on all types of healthy skin, without distinction of ethnicity, gender or age. It then has a complexion-perfecting effect, preferably complexion-perfecting, moisturizing and anti-aging effects on all types of healthy skin. Thus, the invention also relates to the cosmetic use of the active ingredient according to the invention comprising at least one extract obtained from the seeds of Medicago saliva, said extract comprising at least 35% sugars and at most 25% proteins, for its complexion-perfecting effect on all types of healthy skin, preferably its cumulative complexion-perfecting, moisturizing and anti-aging effects.

[0084] The active ingredient according to the invention thus makes it possible to meet the needs of so-called mixed and multi-ethnic beauty. Indeed, the active ingredient according to the invention or the composition according to the invention acts preferentially on all skin types, in particular Caucasian and Asian and African-American and Hispanic-American skin.

[0085] Thus, according to a particularly interesting object, the invention relates to the cosmetic use of the active ingredient according to any of the embodiments previously described or of a composition comprising it, intended for a cosmetic treatment in topical application to the skin, for its complexion-perfecting effects, or its cumulative complexion-perfecting, moisturizing and anti-aging effects on healthy skin of Caucasian and Asian and African-American and Hispanic-American type.

[0086] The invention is now illustrated by non-limiting examples of compositions according to the invention and by results. Examples

[0087] Example 1: Active ingredient according to the invention

[0088] The active ingredient of Example 1 is obtained from alfalfa of the species Medicago sativa. The active ingredient of Example 1 is obtained by the following process: a. Solubilization of Medicago sativa seeds in water at a rate of at least 50g / l, b. Extraction by enzymatic hydrolysis, c. Separation of soluble and insoluble phases, d. Heat treatment, e. Concentration of the soluble phase, f. Purification by ion chromatography, g. Optionally, filtration and sterilizing filtration.

[0089] The active ingredient according to example 1 consists of an extract of Medicago sativa having in particular the following characteristics:

[0090]

[0091]

[0092]

[0093]

[0094]

[0095] - Dry Matter Content = 26.9 g / L, including: - Protein content = 5.2 g / l or 19%, by weight relative to the material dried, - Mineral content = 9% by weight relative to dry matter, - Total sugar content = 20.1 g / L, or 72% by weight relative to the material dried, - 49% of sugars have a molecular mass between 360 and 3,600 Da and 34% of sugars have a molecular mass between 3600 Da and 1260 kDa, - sugars are made up of 45.9% galactose, 36.6% mannose, 14.4% glucose and 3.1% fructose. Mineral content was determined by weighing the residues from incineration at 550°C in an electric muffle furnace to obtain the mineral ash content. Protein content was determined according to the LOWRY method (Lowry et al., Protein measurement with the folin reagent, J. Biol. Chem., 193,265, 1951). Evaluation of the effectiveness of the active ingredient according to the invention Test 1 - In vitro evaluation of the effectiveness of the active ingredient according to the invention on epidermal functions. The objective of this study is to evaluate the effectiveness of the active ingredient according to the invention on epidermal functions. Maintaining the epidermal barrier helps protect the skin. However, several protein components are essential for establishing and maintaining this barrier function, namely: - Ki-67, a key marker of proliferation of cells in the basal layer of the epidermis; - loricrin, a protein playing a key role in terminal differentiation; - Claudin-1, a major constituent of tight junctions responsible for cell cohesion. Water homeostasis is also an essential element in the physiological balance of the skin. Its maintenance is guaranteed by a set of fine regulations based in particular on specific biological markers such as T aquaporin 3. Finally, the dermo-epidermal junction performs several fundamental functions within the skin. In particular, it plays a role in mechanical support for the adhesion of the epidermis to the dermis and as a selective barrier allowing the control of molecular and cellular exchanges between these two compartments. This dermo-epidermal junction is made up of several proteins involved in maintaining its integrity. as : integrin b4, a transmembrane molecule at the level of hemidesmosomes and laminin receptor; laminin 332 present at the level of the anchoring filaments; collagen VII located at the level of the anchoring fibrils.

[0096] Therefore, this study aims to evaluate these different markers. It was carried out by immunohistofluorescence and by staining on young and old reconstructed skin for lipid staining, in the presence of a fluorescent probe. Immunohistofluorescence labeling was carried out with anti-Ki-67, anti-loricrin, anti-claudin-1, anti-aquaporin 3, anti-integrin [34, anti-laminin 332 and anti-collagen VII antibodies, allowing the synthesis of each protein to be measured.

[0097] The results are presented in Tables 1 and 2, describing respectively the results on the physical and water barrier, as well as on the anchoring of the epidermis to the dermis.

[0098] [Tables 1] Young reconstructed skins Old reconstructed skins Control INVENTION 0.5% Control INVENTION 0.5% Ki-67 Ki-67 positive cells (%) 42 56 27 44 Capacity to increase synthesis (%) +33 Capacity to restore synthesis (%) +113 Loricrin Synthesis (xlO4 AU) 490 589 255 368 Capacity to increase synthesis (%) +20 Capacity to restore synthesis (%) +48 Claudin-1 Synthesis (xlO4 AU) 345 424 205 338 Capacity to increase synthesis (%) +23 Capacity to restore synthesis (%) +95 Neutral lipids Synthesis (xlO5 AU) 240 413 61 101 Capacity to increase synthesis (%) +72 Capacity to restore synthesis (%) +22 Aquaporin 3 Synthesis (xlO5 AU) 201 255 109 180 Ability to increase synthesis (%) +27 Ability to restore synthesis (%) +77

[0099] [Tables2] Young reconstructed skins Old reconstructed skins Control INVENTION 0.5% Control INVENTION 0.5% Integrin b4 Synthesis (xlO4 AU) 456 585 309 380 Capacity to increase synthesis (%) +28 Capacity to restore synthesis (%) +48 Laminin 332 Synthesis (xlO5 AU) 539 643 481 592 Capacity to increase synthesis (%) +19 Capacity to restore synthesis (%) +191 Collagen VII Synthesis (xlO4 AU) 110 134 72 88 Capacity to increase synthesis (%) +22 Capacity to restore synthesis (%) +42

[0100] Tested at 0.5% on young and aged reconstructed skin, the active ingredient according to the invention significantly increases the synthesis of proteins of the physical and water barrier, as well as those involved in anchoring the epidermis to the dermis. The active ingredient according to the invention thus makes it possible to maintain a functional epidermal barrier.

[0101] Test 2 - In vitro evaluation of the efficacy of the active ingredient according to the invention on mixed and multi-ethnic pro-collagen activity.

[0102] The objective of this study is to evaluate the capacity of the active ingredient according to the invention to strengthen and preserve the dermal matrix.

[0103] The study was carried out by ELISA assay on human fibroblasts, subjected or not to UVA exposure. The fibroblasts came from women or men, young or mature, and of different ethnicities (Caucasian, Asian, African-American).

[0104] The protocol is as follows. Human fibroblasts are seeded and incubated at 37°C, then they are treated with the active ingredient according to the invention at 0.25%, 0.50% and 1.00% (V / V). The cells are then incubated at 37°C and the supernatants are recovered and stored at -80°C pending the ELISA assay. For the study of the MMP-1 level, the fibroblasts are irradiated with a UV lamp.

[0105] The results are presented in Tables 3 and 4 below.

[0106] [Tables3] Collagen I synthesis (ng / mg protein) Efficacy (%) Control INVENTION 1.00% INVENTION 1.00% / Control Caucasian Young women 354 1509 +326 Young men 299 1127 +277 Mature women 294 1231 +319 Mature men 357 1786 +400 Asian Mature women 261 788 +202 Mature men 258 844 +227 African American Young women 294 711 +142

[0107] [Tables4] MMP-1 synthesis (ng / mg protein) Capacity to limit MMP-1 synthesis (%) Non-irradiated fibroblasts Irradiated fibroblasts Control Control INVENTION 1.0% INVENTION 1.0% / Control Caucasian Young women 10 99 63 +40 Young men 5 106 77 +29 Mature women 2 62 30 +53 Mature men 13 69 45 +43 Asian Mature women 28 76 61 +31 Mature men 8 103 51 +55 African American Young women 1 11 6 +50

[0108] Tested at 1%, on mixed human fibroblasts, of different ages and different ethnicities, the active ingredient according to the invention significantly stimulates the synthesis of collagen I and significantly limits the synthesis of MMP-1 regardless of sex, age and ethnicity. Thus, the active ingredient according to the invention preserves and strengthens the dermal matrix regardless of the skin type.

[0109] Test 3 - In vivo evaluation of the efficacy of the active ingredient according to the invention,

[0110] The biological activities and cosmetic benefits of the active ingredient according to the invention at 2.5% in emulsion were evaluated in vivo, in mixed panels, composed of young and mature subjects from different ethnic groups.

[0111] The composition of the facial study panels is detailed in Table 5 below.

[0112] [T ableaux5 ] Young panels Products tested and application methods Number of subjects / average age Caucasian - placebo formula - formula containing the active ingredient according to the invention at 2.5% 21 days of twice-daily application on half-face - 20 healthy subjects: (2 men and 18 women) - average age 36 years Hispanic-American - placebo formula - formula containing the active ingredient according to the invention at 2.5% 21 days of twice-daily application on the whole face Placebo group: - 29 healthy subjects (9 men and 20 women) - average age 23 years INVENTION group: - 25 healthy subjects (6 men and 19 women) - average age 23 years Afro-American - formula containing the active ingredient according to the invention at 2.5% 21 days of twice-daily application on the whole face INVENTION group: - 30 healthy subjects (6 men and 24 women) - average age 34 years Mature panels Products tested and application methods Number of subjects / average age Caucasian - placebo formula - formula containing the active ingredient according to the invention at 2,5% in emulsion 42 days of twice-daily application to the whole face Placebo group: - 19 healthy subjects (1 man and 18 women) - average age 64 years INVENTION group: - 19 healthy subjects (19 women) - average age 64 years Asian - placebo formula - formula containing the active ingredient according to the invention at 2.5% 42 days of twice-daily application to half-face - 34 healthy subjects (34 women) - average age 55 years,

[0113] Test 3.1 - Evaluation of the quality of the barrier function on the young Caucasian panel

[0114] To assess the quality of the barrier function, insensible water losses were measured using a Tewameter. The results are presented in Table 6 below.

[0115] [Tableauxô] Variation / D0 (%) D7 D21 Placebo 4.2 6.2 Active ingredient 2.5% -8.5 -12.6 Variation / Placebo (%) -12.6 -18.8

[0116] From 7 days of twice-daily application, the active ingredient according to the invention formulated at 2.5% significantly improves the quality of the skin barrier of young Caucasian volunteers through the reduction of water loss. This effect intensifies after 21 days of treatment. The active ingredient according to the invention thus promotes the strengthening of the barrier function.

[0117] Test 3.2 - Evaluation of the capacity to reduce protein oxidation on the young Caucasian panel

[0118] Oxidized proteins were studied by fluorescent labeling on strippings. After 7 days of twice-daily treatment with the active ingredient according to the invention at 2.5%, the quantity of oxidized proteins present on the surface of the skin of young Caucasian subjects decreased by 11.1%. This effect was maintained after 21 days of treatment with a reduction in the level of oxidized proteins of 10.5%.

[0119] By reducing the formation of oxidized proteins, the active ingredient according to the invention improves the transmission of light through the stratum corneum and thus contributes to improving the radiance of the skin.

[0120] Test 3.3 - Evaluation of cell renewal on the young and mature Caucasian panel

[0121] The evaluation of cell renewal was carried out on the inner side of the forearms of a panel composed of 19 subjects with an average age of 34 years (3 men and 16 women) and 17 subjects with an average age of 67 years (1 man and 16 women). This study was carried out from photographs taken at regular intervals over 14 days, using a C-Cube dermoscope. The active ingredient according to the invention at 2.5% in emulsion and the placebo formula were applied to the inner side of the forearms on an area previously defined and colored using a formula containing dihydroxyacetone (DHA): - 14 days before coloring (pre-treatment phase). - 14 days following coloring (treatment phase).

[0122] The results are presented in [Fig.l] and in [Fig.2].

[0123] The active ingredient according to the invention at 2.5% stimulates epidermal renewal in both young and mature Caucasian volunteers: DHA is eliminated more quickly after treatment with the active ingredient according to the invention compared to the placebo formula. This therefore promotes epidermal renewal in young and mature Caucasian volunteers by significantly increasing the capacity of their skin to eliminate DHA from 2 days after its application.

[0124] Test 3.4 - Evaluation of the quality of the dermal matrix on the mature Caucasian panel

[0125] The study of the quality of the fibers was carried out by LC-OCT (results presented in [Fig.3]) and the study of the density of the dermis was carried out by high frequency ultrasound.

[0126] The results of the high-frequency ultrasound are presented in Table 7 below.

[0127] [Tables7] Variation / D0 (%) D21 D42 Placebo -2.0 -1.3 Active ingredient 2.5% 7.7 13.2 Variation / Placebo (%) 9.7 14.5

[0128] The active ingredient according to the invention formulated at 2.5% in emulsion promotes the restructuring of the dermal matrix altered with age in mature Caucasian volunteers. From 21 days of treatment, in comparison before treatment, the active ingredient according to the invention makes it possible to lengthen the fibers of the dermal matrix, thus improving the quality of the fibers of the dermal matrix by 14.5%. Furthermore, the dermal density is also increased by 7.7%. These effects intensify after 42 days of treatment.

[0129] Test 4 - In vivo evaluation of the effectiveness of the active ingredient according to the invention on its capacity to act as a complexion perfector

[0130] Test 4.1 - Assessment of complexion radiance

[0131] Skin radiance was studied by clinical scoring in young and mature Caucasian subjects as well as in African-American, Asian-American and Hispanic-American subjects using a Glossymeter.

[0132] The results are presented in [Fig.4].

[0133] As early as 15 minutes after a single application, a significant improvement in skin radiance is measured for the Caucasian, Asian and African-American panels. Advantageously, this effect continues and intensifies after 21 days of treatment with a significant increase in the radiance parameter of the complexion observed: - in young Caucasians: +10.9%, - in young African-Americans: +30.7%, - in mature Caucasian and Asian subjects: respectively +11.2% and +19.4%.

[0134] Thus, the active ingredient according to the invention enhances the radiance of the complexion immediately and continuously. This effect is multi-ethnic.

[0135] Test 4.2 - Evaluation of post-inflammatory hyperpigmentation in young Hispanic-American and African-American panels.

[0136] The complexion can be affected by the presence of spots such as hyperpigmentation marks. Reducing these pigmentary disorders helps to even out the complexion.

[0137] Post-inflammatory hyperpigmentation marks were studied by analysis of images from the Hispanic-American panel and by clinical scoring in African-American subjects.

[0138] The results are presented in Table 8 below.

[0139] [Tables8] Variation / D0 (%) D7 D21 Hispanic-American -17.5 -21.7 African-American -8.9 -16.6

[0140] From 7 days, the active ingredient according to the invention significantly reduces the visibility of recent post-inflammatory hyperpigmentation marks: by 17.5% in Hispanic-American subjects and by 8.9% in African-American subjects. This effect is further accentuated after 21 days of treatment with a reduction in pigmentary disorders in Hispanic-American subjects of 21.7% and in African-American subjects of 16.6%.

[0141] The active ingredient according to the invention thus demonstrates a rapid anti-pigmentation disorder effect and thus contributes to homogenizing the complexion. This effect is multi-ethnic.

[0142] Test 4.3 - Study of senescence tasks on mature Caucasian and Asian panels

[0143] The natural aging of the skin is a phenomenon which notably leads to the appearance of age spots. In order to maintain an even complexion, it is possible to try to reduce the visibility of these spots.

[0144] Senescence tasks were studied by analysis of images from C-Cube in Caucasian subjects and by measurement using a Mexameter in Asian subjects.

[0145] The results are presented in Table 9 below.

[0146] [Tables9] Variation / D0 (%) D21 D42 Caucasian -5.7 -7.5 Asian -18.2 -26.6

[0147] From 21 days of treatment with the active ingredient according to the invention, the appearance of senescence spots is significantly reduced in mature Caucasian and Asian volunteers. This effect intensifies after 42 days of treatment with a reduction in the visibility of the spots of 7.5% in Caucasian subjects and 26.6% in Asian volunteers.

[0148] Thus, the active ingredient according to the invention also reduces the appearance of spots on mature skin and thus helps to maintain a uniform complexion. This effect is multi-ethnic.

[0149] Test 5 - Evaluation of the hydrating-smoothing effect of the active ingredient according to the invention

[0150] Test 5.1 - Evaluation of the hydration rate on young Caucasian, Hispanic-American and African-American panels.

[0151] The study of the hydration rate of young Caucasian, Hispanic-American and African-American panels was carried out using a Corneometer.

[0152] The results are presented in Table 10 below.

[0153] [TableauxlO] Variation / D0 (%) D7 D21 Caucasian 14.6 17.7 Hispanic-American 43.3 65.9 African-American 13.0 7.1

[0154] From 7 days of use, a significant increase in skin hydration with the active ingredient according to the invention is measured. The active ingredient according to the invention thus has a moisturizing effect. This effect is multi-ethnic.

[0155] Test 5.2 - Evaluation of microrelief on young Caucasian, Hispanic-American and African-American panels

[0156] The study of the smoothing effect was carried out by fringe projection in Caucasian subjects, by image analysis in Hispanic-American subjects and by clinical scoring in African-American subjects.

[0157] The results are presented in Table 11 below.

[0158] [Tableauxll] Variation / D0 (%) D7 D21 Caucasian -6.1 -3.9 Hispanic-American 0 -13.2 African-American -9.5 -26.2

[0159] From 7 days of use, the active ingredient according to the invention significantly promotes the smoothing of microrelief and fine lines in young Caucasian and African-American subjects. This effect is accentuated after 21 days of treatment in the Hispanic-American and African-American panels, with a significant decrease of 13.2% and 26.2%.

[0160] The active ingredient according to the invention thus has a smoothing effect contributing to an improvement in the quality of the skin surface; this effect is multi-ethnic.

[0161] Test 5.3 - Evaluation of skin texture on young Caucasian and African-American panels

[0162] The study of the appearance of skin texture was carried out by clinical scoring in Caucasian and African-American subjects and by image analysis in Hispanic-American subjects.

[0163] The results are presented in Table 12 below.

[0164] [Tables 12] Variation / D0 (%) D7 D21 Caucasian -12.7 -14.3 Hispanic American -10.6 -13.1 African American -15.7 -21.7

[0165] From 7 days, the active ingredient according to the invention significantly reduces the visibility of the pores of the skin of Caucasian subjects by 12.7% and of African-American subjects by 15.7% and tends to refine the pores of Hispanic-American subjects. This effect is accentuated after 21 days of treatment with a significant reduction in the visibility of the pores of 14.3% in Caucasian volunteers, and 21.7% in African-American subjects. A decrease of 13.1% could also be observed in Hispanic-American subjects.

[0166] Thus, by reducing the visibility of pores, the active ingredient according to the invention refines the skin texture and makes it possible to improve the aesthetic problems linked to the problems of young skin in different populations.

[0167] Test 6 - Evaluation of the anti-aging action of the active ingredient according to the invention

[0168] Test 6.1 - Evaluation of the anti-wrinkle effect on mature Caucasian and Asian panels

[0169] The evaluation of the anti-wrinkle effect was carried out by projection of fringes in mature Caucasian and Asian subjects.

[0170] The results are presented in Table 13 below.

[0171] [Tablesl3] Variation / D0 (%) D7 D21 D42 Caucasian -7.9 -10.8 -8.5 Asian -11.7 -11.3 -17.8

[0172] The active ingredient according to the invention formulated at 2.5% exhibits an anti-wrinkle effect in mature volunteers from 7 days of use with a significant reduction in wrinkles of 7.9% in Caucasian volunteers and 11.7% in Asian volunteers. This effect continues after 21 and 42 days for both panels. Thus, the active ingredient according to the invention exhibits a rapid and lasting anti-wrinkle effect, regardless of skin type.

[0173] Test 6.2 - Study of firmness on mature Caucasian and Asian panels

[0174] Skin firmness assessment was performed using a Cutometer in mature Caucasian and Asian subjects.

[0175] The results are presented in Table 14 below.

[0176] [Tablesl4] Variation / D0 (%) D21 D42 Caucasian 12.7 15.7 Asian 4.1 10.8

[0177] From 21 days of treatment, the active ingredient according to the invention formulated at 2.5% significantly improves the firmness of the skin of Caucasian volunteers by 12.7%. This effect intensifies after 42 days of treatment with a significant increase 15.7% firmness in Caucasian volunteers; 10.8% in Asian volunteers. Thus, by improving the firmness of mature skin regardless of skin type, the active ingredient according to the invention offers powerful anti-aging power.

[0178] Example 2: Active ingredient outside the invention

[0179] The product of Example 2 is obtained from an extract of the species Ceratonia siliqua known for its richness in galactomannans. The product of Example 2 is obtained by the following process: a. Solubilization of Ceratonia siliqua seeds in water at a rate of at least 50 g / l, b. Extraction by enzymatic hydrolysis, c. Separation of soluble and insoluble phases, d. Heat treatment, e. Concentration of the soluble phase.

[0180] The product according to example 3 consists of an extract of Ceratonia siliqua seeds having in particular the following characteristics: - Dry Matter Content = 61.4 g / L, including: - Protein content (dosage according to the Lowry method) = 7.2 g / l or 12%, in weight relative to dry matter, - Total sugar content = 52 g / L, or 85% by weight relative to dry matter, - 100% have a molecular mass between 360 Da and 100 kDa.

[0181] The efficacy results, namely the synthesis of collagen I on human fibroblasts, are presented in Table 15 below.

[0182] [Tables 15] Collagen I synthesis (ng / mg protein) Efficiency (%) Control 344 INVENTION - Example 1 at 0.5% 1005 +192 INVENTION - Example 1 at 1.0% 1425 +314 NON-INVENTION - Example 2 at 0.5% 297 - NON-INVENTION - Example 2 at 1.0% 317 -

[0183] This active ingredient obtained by a process similar to the invention, but on a different raw material, shows no effectiveness on the synthesis of collagen I. Thus, the activity of the active ingredient according to the invention is linked to the size and structure of the galact- specific tomannans from Medicago sativa.

[0184] Example 3: Composition according to the invention

[0185] An example of a formulation comprising the active ingredient according to the invention in the form of an anti-aging serum is presented in Table 16 below.

[0186] [Tables 16] Ingredients % Al Purified Water qs 100 Preservative qs Erythritol 3.00 A2 Sclerotium Gum & 6.00 D Polyacrylate-13 & Polyisobutene & Polysorbate 20 0.50 E Active ingredient Invention 2.50

[0187] The composition of Example 3 can in particular be obtained by the following process: - Add A2 to Al with stirring and heat to 70°C. - Place B under stirring and heat to 70°C. - Emulsify B in A under shearing agitation for 10 minutes. - At 60°C, add C under shear stirring. Stir for 5 minutes. - At room temperature, with gentle stirring, add D then E.

[0188] The composition then appears in the form of a fluid, shiny, off-white emulsion.

[0189] Example 4: Composition according to the invention

[0190] An example of a formulation comprising the active ingredient according to the invention in the form of a smooth firming cream is presented in Table 17 below.

[0191] [Tablesl7] Ingredients % Al Purified Water qsp 100 Preservative qs Butylene Glycol 4.00 A2 Glycerin 2.00 Sclerotium Gum & Xanthan Gum 0.30 B Cetearyl Alcohol & Cetearyl Glucoside 2.00 Coco-Glucoside & Coconut Alcohol 2.00 CIO-18 Triglycerides 1.00 Oleyl Erucate 5.00 Isocetyl Stearate 4.00 Dicaprylyl Carbonate 6.00 Propanediol Dicaprylate 4.00 Dimethicone 2.00 Acrylates / C 10-30 Alkyl Acrylate Crosspolymer 0.30 C Active Ingredient Invention 2.50 D Soda Solution 28% qsp pH

[0192] The composition of Example 4 can in particular be obtained by the following process: - Add A2 to Al while stirring and heat to 80°C - Place B under stirring and heat to 80°C. - Emulsify B in A under shearing agitation for 10 minutes. - At room temperature, with gentle stirring, add C. - Adjust pH to 5.0 - 5.5 with D.

[0193] The composition then appears in the form of a very thick emulsion of off-white color.

[0194] Example 5: Composition according to the invention

[0195] An example of a formulation comprising the active ingredient according to the invention in the form of a smoothing cream gel is presented in Table 18 below.

[0196] [Tablesl8] Ingredients % A Purified Water qsp 100 Butylene Glycol 3.00 Glycerin 2.00 Propylene Glycol 2.00 B Acrylates / C 10-30 Alkyl Acrylate Crosspolymer 0.40 C Caprylic / Capric / Succinic Triglyceride 4.00 Dicaprylyl Carbonate 4.00 Octyldodecanol 4.00 Ricinus Communis (Castor) Seed Oil 2.00 Tocopherol 0.01 D Sodium Chloride Solution 28% qsp pH E Preservative qs F Active Ingredient Invention 2.50 G Silica 2.00

[0197] The composition of Example 5 can in particular be obtained by the following process: - Disperse B in A with moderate stirring. - Add C to AB with vigorous stirring. - Adjust the pH with D to 5.0 - 5.5. - Keep stirring for 10 minutes. - With moderate stirring, add E, F and G.

[0198] The composition then comes in the form of a shiny, off-white cream gel.

[0199] Example 6: Composition according to the invention

[0200] An example of a formulation comprising the active ingredient according to the invention in the form of an anti-wrinkle foundation is presented in Table 19 below.

[0201] [Tablesl9] Ingredients % A Tri(Polyglyceryl-3 / Lauryl) Hy-drogenated Trilinoleate 3.00 Cera Alba (Beeswax) 0.40 Magnesium Stearate 0.25 C12-15 Alkyl Benzoate & Stea-ralkonium Hectorite & Propylene Carbonate 7.00 Diisopropyl Sebacate 13.00 B Crambe Abyssinica Seed Oil 7.00 CI 77499 (Iron Oxides) & Isostearyl Sebacate & Disodium Stearoyl Glutamate & Aluminum Hydroxide 0.15 CI 77491 (Iron Oxides) & Isostearyl Sebacate & Disodium Stearoyl Glutamate & Aluminum Hydroxide 0.30 CI 77891 (Titanium Dioxide) & Isostearyl Sebacate & Disodium Stearoyl Glutamate & Aluminum Hydroxide 7.00 CI 77492 (Iron Oxides) & Isostearyl Sebacate & Disodium Stearoyl Glutamate & Aluminum Hydroxide 0.70 C Purified Water qsp 100 Preservative qs Glycerin 4.00 Magnesium Sulfate 1.00 D Kaolin 2.50 E Active ingredient Invention 2.50

[0202] The composition of Example 6 can in particular be obtained by the following process: - Heat A to 80°C and homogenize with vigorous stirring. - Grind B in a three-cylinder mill and transfer to A. Shake until smooth. - Place C under stirring and heat to 80°C. - Add C very slowly to AB while stirring vigorously. - Homogenize for 10 minutes under shearing agitation. - At 30°C, add D then E and homogenize for 1 minute under shearing agitation.

[0203] The composition then appears in the form of a thick, shiny emulsion of light beige color.

Claims

Claims

1. Cosmetic use of an active ingredient comprising galacto-mannans from a hydrolyzate obtained from the seeds of Medicago saliva, for its complexion-perfecting effect on healthy skin.

2. Cosmetic use of an active ingredient according to the preceding claim, characterized in that the healthy skin is healthy Caucasian and Asian and African-American and Hispanic-American skin.

3. Cosmetic use of an active ingredient according to the preceding claim, characterized in that it has complexion-perfecting, moisturizing and anti-aging effects.

4. Cosmetic use of an active ingredient according to one of the preceding claims, characterized in that the sugar fraction of the hydrolyzate comprises at least 60% of galactomannans by weight of the total weight of the sugars of the extract.

5. Cosmetic active ingredient comprising at least one extract obtained from the seeds of Medicago saliva, characterized in that the extract of Medicago sativa comprises, by weight of the total weight of the extract, at least 35% of sugars and at most 25% of proteins.

6. Cosmetic active ingredient according to the preceding claim, characterized in that the sugar fraction of the extract comprises at least 60% of galactomannans by weight of the total weight of the sugars of the extract.

7. Cosmetic active ingredient according to one of claims 5 or 6, characterized in that the sugar fraction of the extract comprises at least 60% of galactomannans with molecular masses between 360 Da (DP2) and 1260 kDa (DP7000), by weight of the total weight of the sugars in the extract.

8. Cosmetic active ingredient according to one of claims 5 to 7, characterized in that the sugar fraction of the extract comprises at least 30% of galactomannans with molecular masses between 3.6 kDa (DP20) and 1260 kDa (DP7000), by weight of the total weight of the sugars in the extract.

9. Cosmetic active ingredient according to one of claims 5 to 8, characterized in that the Medicago sativa extract is a hydrolyzate.

10. Cosmetic active ingredient according to the preceding claim, characterized in that the Medicago sativa hydrolyzate is an enzymatic hydrolyzate.

11. Cosmetic active ingredient according to one of claims 5 to 10, ca- characterized in that the extract is capable of being obtained by the process comprising the following steps: a. Solubilization of Medicago sativa seeds in water at a rate of at least 50 g / l, b. Extraction by hydrolysis, preferably enzymatic hydrolysis, cd Separation of the soluble and insoluble phases, Heat treatment, ef Concentration of the soluble phase, Purification by ion chromatography, g- Optionally, filtration and sterilizing filtration.

12. Cosmetic composition comprising at least 0.1% of a cosmetic active ingredient according to one of claims 5 to 11, by weight of the total weight of the composition.

Images